Streetbeat News

NTRBW

Nutriband Inc.

Industry

Biotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Nutriband Inc. has signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for Aversa Fentanyl, an abuse-deterrent fentanyl patch. This agreement will enable Kindeva to develop the manufacturing process and produce clinical supplies for FDA-required studies. Aversa Fentanyl, which combines Nutriband's proprietary technology with Kindeva's FDA-approved patch system, has a potential market of $80M - $200M in annual US sales. The technology aims to improve safety while ensuring access for patients in need.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 2:21 pm

Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) has increased its existing credit line to $5 million to support the continued development and regulatory submission process for its patented lead product platform, AVERSA™ Fentanyl. The company is targeting FDA submission for AVERSA™ Fentanyl in the first half of 2024. AVERSA™ Fentanyl, which combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva Drug Delivery’s FDA-approved transdermal fentanyl patch system, is estimated to reach peak annual US sales of $80M - $200M.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:21 pm

Nutriband Inc. has received a Notice of Allowance from the USPTO for its patent application covering Aversa™ abuse deterrent technology. The USPTO is expected to issue a U.S. patent after administrative processes are completed.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.